Repligen Corporation (RGEN): Price and Financial Metrics
GET POWR RATINGS... FREE!
RGEN POWR Grades
- RGEN scores best on the Sentiment dimension, with a Sentiment rank ahead of 85.7% of US stocks.
- The strongest trend for RGEN is in Momentum, which has been heading down over the past 179 days.
- RGEN ranks lowest in Momentum; there it ranks in the 14th percentile.
RGEN Stock Summary
- With a price/earnings ratio of 79.49, Repligen Corp P/E ratio is greater than that of about 91.2% of stocks in our set with positive earnings.
- The price/operating cash flow metric for Repligen Corp is higher than 94.37% of stocks in our set with a positive cash flow.
- With a price/sales ratio of 15.21, Repligen Corp has a higher such ratio than 90.67% of stocks in our set.
- Stocks that are quantitatively similar to RGEN, based on their financial statements, market capitalization, and price volatility, are MLAB, ICHR, LUNG, OMCL, and NVRO.
- RGEN's SEC filings can be seen here. And to visit Repligen Corp's official web site, go to www.repligen.com.
RGEN Valuation Summary
- RGEN's EV/EBIT ratio is 123.6; this is 321.84% higher than that of the median Healthcare stock.
- Over the past 243 months, RGEN's price/sales ratio has gone down 6.
- RGEN's price/earnings ratio has moved up 167.9 over the prior 243 months.
Below are key valuation metrics over time for RGEN.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
RGEN | 2021-08-31 | 30.6 | 9.7 | 155.7 | 123.6 |
RGEN | 2021-08-30 | 30.6 | 9.7 | 155.6 | 123.6 |
RGEN | 2021-08-27 | 29.8 | 9.5 | 151.7 | 120.4 |
RGEN | 2021-08-26 | 29.5 | 9.4 | 150.0 | 119.0 |
RGEN | 2021-08-25 | 29.6 | 9.4 | 150.7 | 119.6 |
RGEN | 2021-08-24 | 29.2 | 9.3 | 148.7 | 117.9 |
RGEN Growth Metrics
- The 2 year revenue growth rate now stands at 83.76%.
- The 3 year cash and equivalents growth rate now stands at 265.49%.
- Its 2 year net income to common stockholders growth rate is now at -19.35%.

The table below shows RGEN's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2021-12-31 | 670.534 | 119.016 | 128.291 |
2021-09-30 | 592.661 | 84.267 | 118.879 |
2021-06-30 | 508.505 | 83.273 | 99.933 |
2021-03-31 | 433.007 | 62.357 | 79.561 |
2020-12-31 | 366.26 | 62.625 | 59.926 |
2020-09-30 | 327.086 | 65.428 | 43.832 |
RGEN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RGEN has a Quality Grade of C, ranking ahead of 39.46% of graded US stocks.
- RGEN's asset turnover comes in at 0.293 -- ranking 157th of 682 Pharmaceutical Products stocks.
- ORMP, MESO, and AWH are the stocks whose asset turnover ratios are most correlated with RGEN.
The table below shows RGEN's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.293 | 0.586 | 0.452 |
2021-06-30 | 0.278 | 0.588 | 0.369 |
2021-03-31 | 0.257 | 0.574 | 0.269 |
2020-12-31 | 0.235 | 0.572 | 0.186 |
2020-09-30 | 0.229 | 0.576 | 0.144 |
2020-06-30 | 0.215 | 0.569 | 0.109 |
RGEN Price Target
For more insight on analysts targets of RGEN, see our RGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $267.88 | Average Broker Recommendation | 1.35 (Strong Buy) |
RGEN Stock Price Chart Interactive Chart >
RGEN Price/Volume Stats
Current price | $165.88 | 52-week high | $327.32 |
Prev. close | $160.33 | 52-week low | $137.21 |
Day low | $160.71 | Volume | 776,900 |
Day high | $166.41 | Avg. volume | 505,262 |
50-day MA | $154.83 | Dividend yield | N/A |
200-day MA | $214.96 | Market Cap | 9.03B |
Repligen Corporation (RGEN) Company Bio
Repligen Corporation develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company was founded in 1981 and is based in Waltham, Massachusetts.
Latest RGEN News From Around the Web
Below are the latest news stories about Repligen Corp that investors may wish to consider to help them evaluate RGEN as an investment opportunity.
Agios (AGIO) Gets FDA Nod for Rare Anemia Drug MitapivatAgios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder. |
Repligen (RGEN) Q4 Earnings and Revenues Surpass EstimatesRepligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022. |
Repligen (RGEN) CEO, Tony Hunt on Q4 2021 Results - Earnings Call TranscriptRepligen Corporation (RGEN) Q4 2021 Earnings Conference Call February 17, 2021 8:30 am ET Company Participants Tony Hunt - President, Chief Executive Officer Jon Snodgres - Chief Financial Officer Sondra Newman - Head of Investor Relations Conference Call Participants Dan Arias - Stifel Jacob Johnson - Stephens Julia Qin -... |
Repligen''s Q4 Earnings Beat Expectations, Issues Solid FY22 GuidanceRepligen Corp (NASDAQ: RGEN ) reported Q4 FY21 sales of $186.5 million , up 72% Y/Y as reported and 73% at constant currency, with organic growth of 69%, beating the consensus of $179.29 million. The base business accounted for 64% of revenue, COVID-related sales accounted for 33% of revenue, and … Full story available on Benzinga.com |
Repligen Reports Fourth Quarter and Full Year 2021 Financial Results— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72% |
RGEN Price Returns
1-mo | -2.45% |
3-mo | -10.00% |
6-mo | -35.68% |
1-year | -13.43% |
3-year | 93.00% |
5-year | 298.75% |
YTD | -37.37% |
2021 | 38.20% |
2020 | 107.17% |
2019 | 75.39% |
2018 | 45.37% |
2017 | 17.72% |
Continue Researching RGEN
Want to see what other sources are saying about Repligen Corp's financials and stock price? Try the links below:Repligen Corp (RGEN) Stock Price | Nasdaq
Repligen Corp (RGEN) Stock Quote, History and News - Yahoo Finance
Repligen Corp (RGEN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...